Agomab Therapeutics
AGMBAGMB · Stock Price
Historical price data
Overview
Agomab Therapeutics is a Belgium-based biotech focused on developing transformative treatments for fibrosis by modulating key growth factor pathways like TGFβ. The company successfully completed a $200 million IPO in February 2026, providing capital to advance its clinical pipeline, which includes both systemic and organ-restricted candidates. Its disciplined strategy targets established biology with innovative drug design to improve efficacy and safety profiles in a market with significant unmet need.
Technology Platform
A platform focused on modulating growth factor pathways, particularly TGFβ, using validated drug modalities (small molecules, antibodies) with innovations in targeted delivery (e.g., inhaled, lung-restricted) to mitigate systemic toxicity and improve therapeutic index in fibrotic diseases.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| AGMB-129 + Placebo | Fibrostenotic Crohn's Disease | Phase 2 | |
| AGMB-447 | IPF | Phase 1 | |
| AGMB-129 | Healthy Volunteers | Phase 1 | |
| AGMB-129 | Fibrostenotic Crohn's Disease | Phase 1 | |
| ORG-129 + Placebo | Healthy Volunteers | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Agomab competes with established IPF therapies (nintedanib, pirfenidone) and a crowded field of biotech companies targeting fibrosis through various mechanisms. Its key differentiator is the lung-restricted delivery of AGMB-447, designed to avoid the systemic toxicities that have plagued previous TGFβ inhibitors.